Bank of America Securities Sticks to Their Buy Rating for Denali Therapeutics (DNLI)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Denali Therapeutics, with a price target of $27.00. The company’s shares closed yesterday at $15.20.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Ahmad is an analyst with an average return of -2.2% and a 49.59% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Sarepta Therapeutics, and PTC Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Denali Therapeutics with a $33.00 average price target, implying an 117.11% upside from current levels. In a report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $32.00 price target.

DNLI market cap is currently $2.18B and has a P/E ratio of -5.41.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year. Most recently, in August 2025, Alexander O. Schuth, the COFO and Secretary of DNLI sold 2,937.00 shares for a total of $39,884.46.